abc
QUICK LINKS:

US Clears Johnson & Johnson Hepatitis C Drug

Created: 11/23/2013 8:19 AM WDIO.com

WASHINGTON (AP) — U.S. regulators have approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections.

The Food and Drug Administration said Friday it approved the drug, a protease inhibitor that blocks a protein needed by the virus to replicate.

The Johnson & Johnson drug is designed to eliminate hepatitis C, the most common form of the liver-destroying virus. It is a daily pill taken in combination with the long-established drug cocktail used to treat the most common form of the virus.

More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that is blamed for 15,000 deaths a year.

Johnson & Johnson is one of a half-dozen companies working to develop more effective treatments for the virus as it threatens to become a major health epidemic among baby boomers and middle-age Americans.

People born between 1945 and 1965 are five times more likely to have the virus than people of other age groups. Many of them contracted the virus by sharing needles or having sex with an infected person in their youth. The disease was also spread by blood transfusions before 1992, when blood banks began testing for the virus.

For the last 20 years, the standard treatment for hepatitis C has involved a grueling one-year regimen of pills and injections. These two antiviral drugs, known as ribavirin and interferon-alpha, cause flu-like side effects including nausea, diarrhea and muscle achiness. The introduction of new drugs from Merck and Vertex Pharmaceuticals in 2011 helped shorten the treatment period and boost cure rates as high as 75 percent.

Olysio appears to be slightly more effective than the standard of care, curing 80 percent of patients who had not previously been treated for the disease, according to studies submitted to the FDA.

More significantly, the drug helped most patients cut the amount of time they had to take the traditional drug cocktail to six months.

Additionally, members of the FDA's advisory panel said the drug's once-a-day dosage should be far more manageable for patients than the current drugs from Merck and Vertex, which require taking 12 pills or six pills a day, respectively.

(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Front Page

  • Fitger's 5K Raises $20K For Young Athletes

    It may not have felt much like spring today, but thousands signed-up to voluntarily run outside. It was the 25th Annual Fitger's 5K this morning and that means racing season in the Northland has officially started. This year, the race raised $20,000 for the Young Athletes Foundation.

  • Post-rehab, Injured Snowy Owl Released in Superior

    A rare snowy owl that was hit by a bus in Washington D.C. and sent to Minnesota for rehab is back in the wild. The owl was released outside Superior Saturday.

  • Worker Aboard Ship in Duluth-Superior Harbor Hospitalized After Falling

    A worker aboard the John J. Boland in the Fraser Shipyard fell in one of the ship's chambers Saturday morning, according to the Superior Fire Department. The department rescued the man and he was transported to a local hospital with non life-threatening injuries.

  • 2 Hospitalized After Lincoln Park House Fire

    Two people are in the hospital after a house fire in Duluth's Lincoln Park neighborhood on Friday. Assistant Fire Chief Bryan Bushey said the damage is estimated at $30,000. There is no word on the conditions of the victims.

  • General Mills Website Policy Could be 'Clicking' Your Rights Away

    Could clicking "like" on a company's Facebook page, entering their sweepstakes, or downloading their coupons cost you your right to take that company to court? Some consumer advocates are raising their eyebrows at the new website privacy policy for General Mills, saying it could do just that. 

 
Advertisement